Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Kennedy v. Plan Administrator for DuPont Savings and Investment Plan
Represented E. I. du Pont de Nemours and Company before the U.S. Supreme Court, resulting in a victory. The more
Trade secret and restrictive covenant litigation in Georgia federal court
Lead counsel on behalf of York International, a large independent supplier of heating, ventilation, air conditioning and refrigeration products, more
Class action litigation involving marine products
Successfully defended class action related to allegedly faulty marine products in federal court in Charleston, South Carolina, resulting in denial of more
ERISA plans for several publicly traded food and beverage manufacturers
Represented several publicly traded food and beverage manufacturers in designing and implementing an integrated plan document and summary plan more